BackInozyme Pharma Overview

Inozyme Pharma Selling, General & Admin

Selling, General & Admin expenses for INZY.

Quarterly SG&A Expenses

$5.41M
↑ 3.34% YoY

As of Mar 31, 2025

Annual SG&A Expenses (TTM)

$20.98M
↑ 8.17% YoY

Trailing 12 months ending Mar 31, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin